Over the last decade, there have been many promising biomarkers such as Cystatin-C, NGAL, KIM-1 that assess the acute renal dysfunction.8 The availability of these new markers offers an unprecedented opportunity for improved evaluation and management of patients with AKI. Here, HAVCR1 is linked to acute kidney injury.